Klövern has entered into a lease agreement with Kemwell for the lease of 9,000
sq.m. at Klövern's property in Uppsala Business Park. The lease will run for 16
½ years at an annual rent of SEK 14 million.
Occupation of what is currently a vacant building at the Fyrislund 6:6 property
in Uppsala will take place in stages, as from 1 July 2010. The company will be
using 9,000 sq. m. The rent will gradually increase, to be payable in its
entirety from 2022 onwards. All operating costs and investments will be paid for
by the tenant from day one.
"This agreement with Kemwell is a great step forward for Klövern in Uppsala",
says Klövern's CEO, Gustaf Hermelin. "We have succeeded in renting out Pfizer's
fully-modern former production facility in its existing, fantastic condition,
and to the right tenant."
Kemwell's move to the Uppsala Business Park involves opening its second
production facility for contract manufacturing of pharmaceuticals in Uppsala.
The new premises will be used for the production of pharmaceutical tablets,
suppositories and capsules. In addition, Kemwell will be leasing 500 sq.m. of
office in an adjacent building. Kemwell is already conducting laboratory
operations in Klövern's property in Uppsala Business Park.
Kemwell is a leading contract manufacturer of pharmaceutical products, with
development operations at a global level. Kemwell has approximately 1,000
employees and will have seven production plants by 2011, of which five in India
and two in Sweden.
"Our new pharmaceutical plant will be characterised by a high degree of
automation and flexibility to meet the high standards for pharmaceutical
production required by existing and new customers", says Agneta Bergvall,
Kemwell's CEO. "The new pharmaceutical plant in Uppsala offers us unique
opportunities, and we are extremely pleased that our owners have decided to
expand in Sweden. Our personnel have many years of experience and a high level
of expertise in full-scale production. Kemwell is currently one of India's
largest contract manufacturers and this expansion will enable us to take market
shares in the European market, for example,"
Gunnar Hedberg, the Chairman of the Uppsala Municipal Executive Committee, says
that "The Uppsala Municipality has been following Klövern's and Kemwell's
operations in Uppsala with considerable interest, and we are happy to welcome
this development, which will enable Kemwell to expand in modern and appropriate
premises. This also confirms that Uppsala fully complies with the demands for
expertise and supportive structures made by an international pharmaceutical
company."
Nyköping, 18 May 2010
Klövern AB (publ)
For further information, please contact:
Gustaf Hermelin, CEO, +46-155-44 33 10, +46-70-560 00 00,
gustaf.hermelin@klovern.se
Britt-Marie Einar, Finance and IR Manager, +46-155-44 33 12, +46-70-224 29 35,
britt-marie.einar@klovern.se
Klövern is a real estate company committed to working closely with customers to
meet their needs for premises and services in Swedish growth regions. Klövern
has business units in ten urban centres: Borås, Karlstad, Kista, Linköping,
Norrköping, Nyköping, Täby, Uppsala, Västerås and Örebro. As at 31 March 2010,
the total value of the properties was approximately SEK 12 billion and the
rental income on an annual basis was SEK 1.4 billion. The Klövern share is
listed on the Nasdaq OMX Nordic Exchange in Stockholm for medium-sized
companies.
Klövern AB (publ), Box 1024, SE-611 29 Nyköping, Sweden. Tel +46-155-44 33 00,
Fax +46-155-44 33 22. Corporate Registration No. 556482-5833. Registered office:
Nyköping, Sweden. Website: www.klovern.se
[HUG#1416592]
